Patient Education Materials for Immobilisation Masks in Radiation Therapy for Adult Head and Neck Cancer Patients: A Scoping Review - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38592655/
Immobilisation masks (IMs) are used for people with head and neck cancer (HNC) undergoing radiation therapy (RT) treatment to ensure accuracy and reproducibility between treatments. Claustrophobia-related mask anxiety in HNC...
A scoping review of Patient Education Materials for head and neck cancer patients undergoing radiation therapy found significant variability in understandability and actionability, highlighting a need for improved resources.
Prevention of weight loss in patients with head and neck cancer in ongoing radiation or chemoradiation therapy-A systematic review and meta-analysis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39018960/
Our results suggest an optimal effect of ONS combined with weekly INC, requiring a focus on enhancing compliance as well as support from a multidisciplinary team to manage adverse treatment...
This systematic review found that combining oral nutritional supplements with individualized nutrition counseling effectively supports weight management in head and neck cancer patients undergoing radiotherapy, emphasizing compliance and multidisciplinary team involvement.
RET kinase inhibitors for the treatment of RET-altered thyroid cancers: Current knowledge and future directions
Source : https://pubmed.ncbi.nlm.nih.gov/38342224/
RET gain-of-function mutations are the most common drivers in medullary thyroid carcinoma, while RET fusions are identified in 5-10% of papillary thyroid carcinomas. Thus, RET plays a major role in...
RET mutations are critical in thyroid cancer, with selective inhibitors showing promise but limited by resistance and toxicity. Ongoing research is essential for developing more effective, definitive treatments.
Rapid response to selpercatinib in RET fusion positive pancreatic neuroendocrine carcinoma confirmed by smartwatch
Source : https://pubmed.ncbi.nlm.nih.gov/39085487/
This case report describes the efficacy of selpercatinib, a selective RET inhibitor, in an unusual case of large-cell neuroendocrine pancreatic carcinoma (LCNEPAC) harboring a CCDC6::RET fusion. A 56-year-old male with...
Selpercatinib demonstrates efficacy in RET fusion-positive large-cell neuroendocrine pancreatic carcinoma, with wearable technology highlighting treatment response, advancing patient-centric care, and establishing digital biomarkers for clinical trials.
Durability of Response With Selpercatinib in Patients With RET-Activated Thyroid Cancer: Long-Term Safety and Efficacy From LIBRETTO-001 - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39094065/
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or...
Selpercatinib demonstrates durable efficacy and a consistent safety profile in patients with RET-mutant medullary thyroid cancer and RET fusion-positive thyroid cancer, with high objective response rates and extended progression-free survival.